EC Clinical and Medical Case Reports

In our study we investigated the effect of application of vitamin C and aspirin therapy for the surviving of patients with Coronavirus disease (COVID-19). 796 patients (male, 54.3%; mean, 61.3 years old) who had positive the chain reaction genetic test real-time with reverse transcriptase (rRT-PCR test) and who had at least three symptoms characteristic of patients with COVID-19 were allocated in two groups. During twenty-six days, investigated group of 398 patients (patients who had sputum expectoration and at least two more symptoms characteristic of patients with COVID-19) took vitamin C and aspirin like a therapy for COVID-19. In twenty-six days with therapy in this group dead 5 patients. Our control group had 398 patients (patients who had myalgia like one of symptoms characteristic of patients with COVID-19 and at least two symptoms more) who used only aspirin per day. In control group dead 29 patients during of twenty-six days of therapy. All patients, 762 who the rest are alive from both of investigated groups made again the rRT-PCR test on the twenty seventh day and no one did not have positive rRT-PCR test. In this study exist statistically significant correlation between COVID-19 surviving and using of vitamin C and aspirin like a therapy for COVID-19 (χ²=2.697; p > 0.05).

 Keywords: Coronavirus; Survivors of the Corona Virus; The Chain Reaction Genetic Test Real-Time with Reverse Transcriptase (rRT-PCR test); Vitamin C and Aspirin Therapy

1. Khan S., et al. “The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options”. Journal of Clinical Microbiology 5 (2020): e00187-20.
2. Vankadari N and Wilce JA. “Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26”. Emerging Microbes and Infections 1 (2020): 601-604.
3. Callaway E. “Coronavirus vaccines: five key questions as trials begin”. Nature 7800 (2020): 481.
4. World Health Organization. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). Geneva: World Health Organization (2020).
5. Guan WJ., et al. “China Medical Treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China”. New England Journal of Medicine 18 (2020): 1708-1720.
6. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet10223 (2020): 507-513.
7. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 10223 (2020): 497-506.
8. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. Journal of the American Medical Association11 (2020): 1061-1069.
9. Sun P., et al. “Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis”. Journal of Medical Virology 6 (2020): 612-617.
10. Rodriguez-Morales AJ., et al. “Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis”. Travel Medicine and Infectious Disease 34 (2020): 101623.
11. Li IQ., et al. “2019 novel coronavirus patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis”. Journal of Medical Virology 6 (2020): 577-583.
12. Lu X., et al. “SARS-CoV-2 infection in children”. New England Journal of Medicine 17 (2020): 1663-1665.
13. Cai J., et al. “A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features”. Clinical Infectious Diseases 6 (2020):1547-1551.
14. Chen ZM., et al. “Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus”. World Journal of Pediatrics 3 (2020): 240-246.
15. Andersen KG., et al. “The proximal origin of SARS-CoV-2”. Nature Medicine (2020).
16. Zou X., et al. “Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection”. Frontiers in Medicine 2 (2020): 185-192.
17. Xu Z., et al. “Pathological findings of COVID-19 associated with acute respiratory distress syndrome”. Lancet Respiratory Medicine 4 (2020): 420-422.
18. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 10223 (2020): 507-513.
19. Wang d., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus -infected pneumonia in Wuhan, China”. Journal of the American Medical Association 11 (2020): 1061-1069.
20. Sun P., et al. “Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis”. Journal of Medical Virology 6 (2020): 612-617.
21. Tang N., et al. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia”. Journal of Thrombosis and Haemostasis 4 (2020): 844-847.
22. Cao B., et al. “A trial of lopinavirritonavir in adults hospitalized with severe Covid-19”. New England Journal of Medicine 19 (2020): 1787-1799.
23. Wu C., et al. “Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China”. JAMA Internal Medicine 7 (2020): 934-943.
24. Xu L., et al. “Liver injury during highly pathogenic human coronavirus infections”. Liver International 5 (2020): 998-1004.
25. Jin M and Tong Q. “Rhabdomyolysis as potential late complication associated with COVID-19”. Emerging Infectious Diseases 7 (2020): 1618-1620.
26. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China”. JAMA Cardiology7 (2020): 802-810.
27. Zhang Y., et al. “Coagulopathy and antiphospholipid antibodies in patients with Covid-19”. New England Journal of Medicine 17 (2020): e38.
28. Fowler AA., et al. “Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomize clinical trial”. Journal of the American Medical Association 13 (2019): 1261-1270.
29. Bing Z., et al. “Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study”. Annals of Palliative Medicine 2 (2021): 1599-609.